An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer.

Trial Profile

An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs E 7820 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 08 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 08 Feb 2011 Planned end date changed from 1 Aug 2012 to 1 Jan 2011 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top